CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-25 | Karlin Dan Chief Medical Officer | Sale 10b5-1 | −6,578 | $9.50 | $62K | 358,452 |
| 2024-03-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −16,519 | $9.50 | $157K | 580,202 |
| 2024-02-27 | Wernli Miri Halperin Executive President | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2024-02-27 | Greenway Schond L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2024-02-27 | Liao Carrie Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-02-27 | Barrow Robert Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2024-02-27 | Sullivan Mark Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2024-02-27 | Karlin Dan Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-12-26 | Karlin Dan Chief Medical Officer | Sale | −6,774 | $3.63 | $25K | 365,030 |
| 2023-12-26 | Barrow Robert Chief Executive Officer | Sale | −13,237 | $3.63 | $48K | 596,721 |
| 2023-12-26 | Greenway Schond L. Chief Financial Officer | Sale | −5,652 | $3.63 | $21K | 216,617 |
| 2023-09-25 | Barrow Robert Chief Executive Officer | Sale | −5,268 | $3.57 | $19K | 619,960 |
| 2023-09-25 | Barrow Robert Chief Executive Officer | Sale | −8,231 | $3.58 | $29K | 611,729 |
| 2023-09-25 | Karlin Dan Chief Medical Officer | Sale | −3,678 | $3.57 | $13K | 375,044 |
| 2023-09-25 | Karlin Dan Chief Medical Officer | Sale | −3,240 | $3.58 | $12K | 371,804 |
| 2023-09-25 | Greenway Schond L. Chief Financial Officer | Sale | −1,908 | $3.57 | $7K | 226,123 |
| 2023-09-25 | Greenway Schond L. Chief Financial Officer | Sale | −3,854 | $3.58 | $14K | 222,269 |
| 2023-08-25 | Greenway Schond L. Chief Financial Officer | Sale | −20,000 | $3.80 | $76K | 228,031 |
| 2023-06-27 | Barrow Robert Chief Executive Officer | Sale | −7,086 | $3.19 | $23K | 631,873 |
| 2023-06-27 | Barrow Robert Chief Executive Officer | Sale | −8,416 | $3.21 | $27K | 623,457 |
Page 6 of 12 · 225 trades